Vista Pharmaceuticals (524711) Q3 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter ended December 31, 2024, and received a limited review report from auditors.

• WHO Certificate awarded to the company, effective as of the results release date.

Financial highlights

• Total revenue for Q3 FY25 was Rs 267.69 lakhs, up from Rs 172.86 lakhs in Q3 FY24.

• Net loss for Q3 FY25 stood at Rs 132.23 lakhs, compared to a net loss of Rs 162.89 lakhs in Q3 FY24.

• Loss before tax for Q3 FY25 was Rs 251.74 lakhs, higher than the loss before tax of Rs 220.12 lakhs in Q3 FY24.

• Earnings per share (basic) for Q3 FY25 was Rs (0.07), compared to Rs (0.33) in Q3 FY24.

Outlook and guidance

• Operations continue to focus solely on manufacturing pharmaceutical products.

• WHO certification is expected to enhance credibility and market opportunities.